We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 896

Cyber Risk News & Trends - December 2017
  • Buchanan Ingersoll & Rooney PC
  • USA
  • December 5 2017

Internet data breaches threaten the usernames and passwords of billions of people, but bad actors find phishing is the most effective way to hijack


Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • November 5 2017

Judge Patti B. Saris denied the Bank of New York Mellon’s (BNY Mellon) motion to strike putative class representative Ashby Henderson. BNY Mellon


Ninth Circuit Analyzes Statements Concerning FDA Feedback, in In re Atossa Genetics, Inc. Securities Litigation (August 18, 2017)
  • Lane Powell PC
  • USA
  • October 4 2017

On August 18, 2017, a Ninth Circuit panel affirmed in part, reversed in part, and vacated in part the district court's dismissal of the amended


Inside the Courts - An Update From Skadden Securities Litigators
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • September 27 2017

The U.S. Supreme Court resolved a circuit split by deciding that the three-year limit for filing lawsuits under Section 13 of the Securities Act is a


Global Privacy & Cybersecurity Update Vol. 15
  • Jones Day
  • USA, European Union, Global
  • September 13 2017

On June 19, the Federal Trade Commission ("FTC") submitted comments to a working group organized by the Department of Commerce's National


FDA Trip Leads to Securities Stumble: The Gravity of Regulatory Due Diligence
  • Arent Fox LLP
  • USA
  • September 7 2017

After three years of litigation, a medical device manufacturer has agreed to pay $7 million to settle a class action lawsuit that claimed the company


First Circuit Affirms Dismissal Of Putative Securities Fraud Class Action, Finding Defendants’ Statements Concerning The Potential NDA For A Drug Candidate Came “Replete with Caveats”
  • Shearman & Sterling LLP
  • USA
  • August 29 2017

On August 22, 2017, the United States Court of Appeals for the First Circuit affirmed an order from the District of Massachusetts, dismissing a


First Circuit Affirms Dismissal of Biogen Investors’ Claims, Finding a Lack of “Connecting Detail,” in In re Biogen Inc. Securities Litigation, 857 F.3d 34
  • Lane Powell PC
  • USA
  • June 21 2017

In this putative class action, investors alleged that Biogen executives misled the public about the impact on sales of the company's multiple


Third Circuit Affirms Dismissal Of Putative Securities Class Action Regarding Rejected FDA Application For Drug Aimed At Reducing Heart Attacks
  • Shearman & Sterling LLP
  • USA
  • June 6 2017

On May 23, 2017, the United States Court of Appeals for the Third Circuit, in a non-precedential opinion, affirmed the dismissal of a putative


On-Sale Bar Under the America Invents Act
  • McDermott Will & Emery
  • USA
  • May 25 2017

The US Court of Appeals for the Federal Circuit interpreted the scope of the on-sale bar provision, 35 USC